
Hereditary angioedema (type 1 or type 2) Program in Pharmaceutical Benefits Scheme (PBS) 012-21112939

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines the PBS subsidised lanadelumab for patients with
hereditary angioedema (HAE) type 1 or 2.

Hereditary angioedema type 1 or 2 and listing dates

Hereditary angioedema is a rare inherited disorder characterised by
recurrent episodes of severe swelling (angioedema) mainly in the limbs,
face, intestinal tract or airway.

Listing dates: lanadelumab – 01 December 2021

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the Complex Drugs
Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details,
restriction and item codes, and the PBS and Services Australia websites.

Related links

Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
